Skip to main content
    L

    Longeveron LLC (LGVN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.50
    -0.23 (-13.29%)

    Market Cap: $5.52M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    37%(7/19)
    Avg Surprise
    -8.84%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.93
    Range$-2.20 - $-1.70
    3 analysts
    EPS Revisions
    1
    0
    7d
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-1.50-28.9%
    60d ago$-1.50-28.9%
    30d ago$-1.70-13.7%
    7d ago$-1.70-13.7%
    Current$-1.93
    Revenue Consensus
    $509000
    Range$327000 - $800000
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-5.34
    Range$-6.00 - $-4.90
    3 analysts
    Revenue Consensus
    $594330
    Range$101000 - $1M
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-5.34---
    Sep 26EST
    		-$-1.93---
    Jun 26
    Reported Aug 12
    		$-0.19$-0.19+0.00%Beat+42.4%
    Mar 26
    Reported May 13
    		$-0.19$-0.17-11.76%Miss+44.1%
    Dec 25
    Reported Mar 17
    		$-2.20$-3.67+40.00%Beat-714.8%
    Sep 25
    Reported Nov 4
    		$-0.39$-0.26-50.00%Miss-14.7%
    Jun 25
    Reported Aug 13
    		$-0.33$-0.35+5.71%Beat+82.0%
    Mar 25
    Reported May 8
    		$-0.34$-0.33-3.03%Miss+78.9%
    Dec 24
    Reported Feb 28
    		$-0.27$-0.20-35.00%Miss+89.2%
    Sep 24
    Reported Nov 12
    		$-0.34$-0.44+22.73%Beat+87.9%
    Jun 24
    Reported Aug 14
    		$-1.83$-0.87-110.34%Miss+32.2%
    Mar 24
    Reported May 14
    		$-1.61$-2.00+19.50%Beat-631.8%
    Dec 23
    Reported Feb 27
    		$-2.50$-2.05-21.95%Miss-19.0%
    Sep 23
    Reported Nov 10
    		$-2.80$-2.40-16.67%Miss-12.0%
    Jun 23
    Reported Aug 11
    		$-2.70$-2.47-9.31%Miss+0.0%
    Mar 23
    Reported May 12
    		$-0.22$-0.21-4.76%Miss+87.1%
    Dec 22
    Reported Mar 10
    		$-2.10$-2.00-5.00%Miss-950.0%
    Sep 22
    Reported Nov 14
    		$-2.50$-2.20-13.64%Miss-900.0%
    Jun 22
    Reported Aug 12
    		$-2.70$-2.27-18.94%Miss-938.5%
    Mar 22
    Reported May 13
    		$-1.70$-2.25+24.44%Beat-844.4%
    Dec 21
    Reported Mar 11
    		$-0.20$-0.25+20.00%Beat-566.7%
    Sep 21
    Reported Nov 12
    		$-0.25N/AN/ABeat+62.0%
    Jun 21
    Reported Aug 13
    		$-0.26N/AN/ABeat-344.4%
    Mar 21
    Reported May 14
    		$-0.18N/AN/ABeat-136.5%
    Dec 20
    Reported Mar 30
    		$-0.03$0.00N/AMiss+87.1%
    Sep 20
    Reported Dec 31
    		$-0.66$0.00N/AMiss-
    Jun 20
    Reported Sep 30
    		$-0.06$0.00N/AMiss-
    Mar 20
    Reported Jun 29
    		$-0.08$0.00N/AMiss-
    Sep 19
    Reported Dec 31
    		$-0.23$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.05EV/EBITDAN/A
    Price/FCF-0.23xFCF Yield-436.28%
    Profitability
    Profit Margin0.00%Operating Margin-2150.00%
    ROE-203.60%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio2.63xQuick Ratio2.63x
    Trading Statistics
    Beta-0.20Avg Volume181.19K
    52-Week High$12.3052-Week Low$1.69

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.26
    SMA 20$2.46
    SMA 50$5.23
    SMA 200$6.86
    EMA 10$2.22
    EMA 20$2.88
    EMA 50$4.43
    EMA 200$6.79

    MACD

    Line: -0.93Signal: -0.98Hist: 0.05

    ADX

    ADX: 29.9+DI: 8.2-DI: 19.6

    Aroon & PSAR

    Aroon Up8.0
    Aroon Down100.0
    PSAR$4.49

    Bollinger Bands

    Upper Band$3.13
    Lower Band$1.78
    %B Position5496%(Upper)
    Band Width-0.21

    RSI (14-Day)

    Oversold
    20.8

    Momentum Oscillators

    Stoch %K4.3
    Stoch %D9.2
    Williams %R-91.5
    ROC (10d)-42.1%
    Momentum-1.09
    CCI (20d)-308.9
    MFI (14d)32.8

    Volatility Measures

    ATR (14d)$0.83(55.6%)
    StdDev (20d)0.34
    Hist Vol120.5%(High)

    Volume Flow

    VWAP$1.53
    OBV233.7M
    AD Line45.6B
    CMF (20d)-0.161

    Volume Metrics

    Avg Vol (20d)112.4K
    Vol Ratio1.3x
    VWMA (20d)$2.44

    Pivot Points

    R3$2.42
    R2$2.26
    R1$2.00
    Pivot Point$1.84
    S1$1.58
    S2$1.42
    S3$1.16

    Advanced Oscillators

    TSI-49.54
    Ultimate Osc26.4
    KST-550.53

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$287,000$398,000$365,000$137,000$316,000$381,000$603,000$773,000$468,000$548,000$63,000$150,000
    Cost of Revenue$105,000$134,000$108,000$12,000$170,000$106,000$74,000$91,000$124,000$219,000$65,000$96,000
    Gross Profit$182,000$264,000$257,000$125,000$146,000$275,000$529,000$682,000$344,000$329,000$-2,000$54,000
    Operating Expenses$6.35M$5.04M$5.66M$7.43M$5.54M$5.46M$4.81M$5.33M$3.84M$4.42M$5.44M$5.21M
    R&D$3.19M$2.32M$2.72M$3.85M$2.95M$2.52M$1.99M$2.21M$1.72M$2.22M$2.16M$1.84M
    SG&A$3.16M$2.72M$2.94M$3.58M$2.59M$2.94M$2.82M$3.13M$2.12M$2.20M$3.28M$3.37M
    Operating Income$-6,171,000$-4,775,000$-5,399,000$-7,310,000$-5,397,000$-5,181,000$-4,283,000$-4,649,000$-3,500,000$-4,090,000$-5,440,000$-5,161,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$45,000$0$0$0$0$0$0$0$181,000$0
    Income Before Tax$-6,073,000$-4,736,000$-5,444,000$-7,221,000$-5,028,000$-5,011,000$-4,083,000$-4,419,000$-3,413,000$-4,058,000$-5,621,000$-5,106,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-6,073,000$-4,736,000$-5,444,000$-7,221,000$-5,028,000$-5,011,000$-4,083,000$-4,419,000$-3,413,000$-4,058,000$-6,028,000$-5,106,000
    EBITDA$-5,852,000$-4,484,000$-5,166,000$-6,957,000$-4,765,000$-4,590,000$-3,841,000$-4,184,000$-3,184,000$-3,806,000$-5,385,000$-4,874,000
    EBIT$-6,073,000$-4,736,000$-5,444,000$-7,221,000$-5,028,000$-5,011,000$-4,083,000$-4,419,000$-3,413,000$-4,058,000$-5,621,000$-5,106,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about LGVN

    News

    Longeveron CEO Stephen H. Willard Discloses RSU Tax Withholding Share Disposal

    Longeveron Inc. CEO Stephen H. Willard disposed of 1,987 shares of Class A Common Stock on October 1, 2026, to cover tax obligations from a restricted stock unit (RSU) award. The shares were withheld at a price of $2.59...

    Kalkine Media•10/6/26•Neutral

    Weekly Recap: ELPIS II misses endpoint and strategic review cites safety

    Longeveron Inc. (LGVN) announced that its Phase 2b ELPIS II trial for laromestrocel in HLHS missed its primary endpoint, showing no RVEF benefit at 12 months, although the safety profile was acceptable. Exploratory data...

    TradingView•9/29/26•Bearish

    LONGEVERON INC. (LGVN) INVESTOR LAWSUIT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against the Longeveron Inc.

    Bernstein Liebhard LLP has reminded investors of Longeveron Inc. (LGVN) about the November 12, 2021, deadline to file a lead plaintiff motion in a securities class action lawsuit. The lawsuit alleges that Longeveron's...

    TMX Newsfile•9/17/26•Bearish

    Longeveron Executes 1-for-10 Reverse Stock Split

    Longeveron (LGVN) recently enacted a 1-for-10 reverse stock split to consolidate its Class A and Class B shares, effective August 26, 2026...

    TipRanks•8/30/26•Somewhat-Bearish

    Longeveron Announces 1-for-10 Reverse Stock Split

    Longeveron Inc. (NASDAQ: LGVN) announced a 1-for-10 reverse stock split for its Class A and Class B common stock, effective August 26...

    BioSpace•8/24/26•Somewhat-Bearish

    LGVN Valuation and Fair Value

    P/E
    -0.1x
    P/FCF
    -0.2x
    P/B
    0.5x
    See GNG's fair value

    LGVN Profitability: Margins, ROIC and FCF

    Gross margin
    69.8%
    Operating margin
    -2150.0%
    Net margin
    0.0%
    ROE
    -203.6%
    FCF margin
    -1735.3%
    FCF yield
    -436.3%

    LGVN Competitors

    CompanyTicker
    enVVeno Medical CorpNVNO
    Scienture Holdings, Inc.SCNX
    Sonoma Pharmaceuticals IncSNOA
    Volitionrx LtdVNRX
    Imunon IncIMNN
    Processa Pharmaceuticals IncPCSA
    Can Fite Biopharma Ltd ADRCANF
    Aptorum Group Ltd Class AAPM

    Sector: Healthcare

    LGVN Analyst Ratings

    Consensus
    Buy
    Analysts
    3
    Strong Buy
    0
    Buy
    2
    Hold
    1
    Sell
    0
    Strong Sell
    0

    LGVN Bull Case vs Bear Case

    Bear case

    • LGVN beat EPS estimates in 37.5% of its last 8 reported quarters.
    • LGVN's quarterly revenue changed -9.2% year over year.

    LGVN Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -3.9%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-1.93
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    Frequently Asked Questions About LGVN

    Does LGVN pay dividends?

    Longeveron LLC (LGVN) does not currently pay a regular dividend.

    What is LGVN's market cap?

    Longeveron LLC (LGVN) has a market capitalization of $5.52M with a current stock price of $1.50.

    Related stocks

    Sector: Healthcare

    All stocks starting with L

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In